Anthony Lucci

List of Publications by Year
in descending order

219	15,058	18482 62	20358 116
papers	citations	h-index	g-index

226	226	226	18714
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
2	Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. Cancer Cell, 2014, 26, 707-721.	16.8	1,293
3	Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011. Journal of Clinical Oncology, 2007, 25, 3657-3663.	1.6	741
4	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
5	Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial. Annals of Surgical Oncology, 2006, 13, 491-500.	1.5	506
6	Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncology, The, 2012, 13, 688-695.	10.7	474
7	International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology, 2011, 22, 515-523.	1.2	407
8	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research, 2012, 18, 6758-6770.	7.0	345
9	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. Ca-A Cancer Journal for Clinicians, 2010, 60, 351-375.	329.8	298
10	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clinical Cancer Research, 2016, 22, 2583-2593.	7.0	289
11	Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil, and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells. Journal of Biological Chemistry, 1997, 272, 1682-1687.	3.4	264
12	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2018, 19, 181-193.	10.7	233
13	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 560-567.	6.3	206
14	Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2â€positive breast cancer. Cancer, 2010, 116, 2884-2889.	4.1	194
15	A CXCR4 Antagonist CTCE-9908 Inhibits Primary Tumor Growth and Metastasis of Breast Cancer. Journal of Surgical Research, 2009, 155, 231-236.	1.6	159
16	American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Annals of Surgical Oncology, 2012, 19, 3144-3151.	1.5	157
17	Factors influencing career choice among medical students interested in surgery. Journal of Surgical Education, 2003, 60, 210-213.	0.7	152
18	Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surgery, 2017, 152, 665.	4.3	149

#	Article	IF	Citations
19	Expression of epithelialâ€“mesenchymal transitionâ€inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. International Journal of Cancer, 2012, 130, 808-816.	5.1	148
20	A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Annals of Surgery, 2018, 267, 946-951.	4.2	147
21	Prospective Assessment of Postoperative Complications and Associated Costs Following Inguinal Lymph Node Dissection (ILND) in Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 2764-2772.	1.5	139
22	Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer. Annals of Surgery, 2006, 244, 464-470.	4.2	135
23	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	7.0	130
24	Brief intervention by surgeons can influence students toward a career in surgery. Journal of Surgical Research, 2003, 111, 166-169.	1.6	128
25	Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 2012, 17, 891-899.	3.7	127
26	Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2006, 13, 310-320.	1.5	120
27	COX-2 involvement in breast cancer metastasis to bone. Oncogene, 2007, 26, 3789-3796.	5.9	120
28	Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Annals of Surgical Oncology, 2016, 23, 3190-3198.	1.5	119
29	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clinical Cancer Research, 2009, 15, 6639-6648.	7.0	113
30	Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Annals of Surgical Oncology, 2011, 18, 2407-2412.	1.5	113
31	National practice patterns of sentinel lymph node dissection for breast carcinoma11No competing interests declared.. Journal of the American College of Surgeons, 2001, 192, 453-458.	0.5	112
32	Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer, 2010, 116, 3330-3337.	4.1	108
33	Evaluation of a Breast Cancer Nomogram for Predicting Risk of Ipsilateral Breast Tumor Recurrences in Patients With Ductal Carcinoma in Situ After Local Excision. Journal of Clinical Oncology, 2012, 30, 600-607.	1.6	107
34	Role of Cyclooxygenase-2 in Breast Cancer. Journal of Surgical Research, 2002, 108, 173-179.	1.6	101
35	Potential Targets to Encourage a Surgical Career. Journal of the American College of Surgeons, 2005, 200, 946-953.	0.5	99
36	Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS ONE, 2016, 11, e0159072.	2.5	94

#	Article	IF	Citations
37	Neoadjuvant Trastuzumab and Docetaxel in Patients With Breast Cancer: Preliminary Results. Clinical Breast Cancer, 2003, 4, 348-353.	2.4	92
38	A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer, 2009, 115, 1555-1562.	4.1	91
39	Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotype. European Journal of Cancer, 2011, 47, 1527-1536.	2.8	89
40	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clinical Cancer Research, 2018, 24, 4416-4428.	7.0	89
41	Local, regional, and systemic recurrence rates in patients undergoing skinâ€sparing mastectomy compared with conventional mastectomy. Cancer, 2011, 117, 916-924.	4.1	87
42	Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist, 2011, 16, 1675-1683.	3.7	86
43	Changing Behavior in Clinical Practice in Response to the ACOSOG Z0011 Trial: A Survey of the American Society of Breast Surgeons. Annals of Surgical Oncology, 2012, 19, 3152-3158.	1.5	85
44	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer, 2018, 9, 1437-1447.	2.5	84
45	Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology, 2014, 25, 358-365.	1.2	82
46	How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer, 2008, 113, 30-37.	4.1	78
47	Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. Annals of Surgical Oncology, 2010, 17, 2899-2908.	1.5	74
48	Conditional survival estimates improve over time for patients with advanced melanoma. Cancer, 2010, 116, 2234-2241.	4.1	74
49	Inflammatory breast cancer: a proposed conceptual shift in the UICCâ€“AJCC TNM staging system. Lancet Oncology, The, 2017, 18, e228-e232.	10.7	74
50	A caution regarding lymphatic mapping in patients with colon cancer. American Journal of Surgery, 2001, 182, 707-712.	1.8	73
51	HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Research and Treatment, 2009, 113, 501-507.	2.5	73
52	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. Journal of the National Cancer Institute, 2014, 106, .	6.3	73
53	COX-2 Induces IL-11 Production in Human Breast Cancer Cells. Journal of Surgical Research, 2006, 131, 267-275.	1.6	72
54	COX-2 overexpression increases motility and invasion of breast cancer cells. International Journal of Oncology, 2005, 26, 1393-9.	3.3	72

#	Article	IF	Citations
55	C-Reactive Protein As a Marker of Melanoma Progression. Journal of Clinical Oncology, 2015, 33, 1389-1396.	1.6	71
56	Melanoma adrenal metastasis: natural history and surgical management. American Journal of Surgery, 2008, 195, 363-369.	1.8	69
57	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 125, 785-795.	2.5	68
58	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment, 2015, 152, 407-416.	2.5	68
59	Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. American Journal of Surgery, 2008, 196, 81-87.	1.8	67
60	Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Annals of Surgical Oncology, 2012, 19, 3777-3784.	1.5	67
61	Involvement of IL-8 in COX-2-Mediated Bone Metastases from Breast Cancer. Journal of Surgical Research, 2006, 134, 44-51.	1.6	66
62	Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. American Journal of Surgery, 2009, 198, 720-725.	1.8	66
63	Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Molecular Cancer, 2010, 9, 180.	19.2	66
64	Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. Journal of Clinical Oncology, 2016, 34, 1741-1747.	1.6	64
65	Inflammatory Breast Cancer. Surgical Clinics of North America, 2018, 98, 787-800.	1.5	63
66	Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer, 2011, 117, 5476-5484.	4.1	61
67	Reduced Incidence of Breast Cancerâ€“Related Lymphedema following Mastectomy and Breast Reconstruction versus Mastectomy Alone. Plastic and Reconstructive Surgery, 2012, 130, 1169-1178.	1.4	61
68	Lymph node ratio predicts diseaseâ€specific survival in melanoma patients. Cancer, 2009, 115, 2505-2513.	4.1	60
69	Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning. Annals of Surgery, 2011, 253, 572-579.	4.2	60
70	Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer, 2011, 117, 39-47.	4.1	59
71	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology, 2018, 4, 1207.	7.1	56
72	Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: A randomized controlled trial (NCT00506311). World Journal of Surgical Oncology, 2008, 6, 63.	1.9	55

#	Article	IF	Citations
73	COX-2 overexpression increases motility and invasion of breast cancer cells. International Journal of Oncology, 2005, 26, 1393.	3.3	54
74	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature, 2022, 606, 797-803.	27.8	54
75	Role of COX-2 in Tumorospheres Derived from a Breast Cancer Cell Line. Journal of Surgical Research, 2011, 168, e39-e49.	1.6	51
76	Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. Annals of Surgical Oncology, 2009, 16, 1606-1611.	1.5	50
77	Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy. Clinical Cancer Research, 2011, 17, 4882-4891.	7.0	48
78	Variability in melanoma post-treatment surveillance practices by country and physician specialty. Melanoma Research, 2012, 22, 376-385.	1.2	48
79	Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma-In Situ Treated with Mastectomy: Is Further Therapy Warranted?. Annals of Surgical Oncology, 2013, 20, 4103-4112.	1.5	48
80	Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage Iâ€“III Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2015, 22, 552-558.	1.5	48
81	Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Research, 2013, 23, 290-297.	1.2	47
82	Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clinical and Experimental Metastasis, 2010, 27, 233-240.	3.3	46
83	The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 2006, 107, 1248-1254.	4.1	44
84	Ductal Carcinoma-In-Situ of the Breast with Subsequent Distant Metastasis and Death. Annals of Surgical Oncology, 2011, 18, 2873-2878.	1.5	44
85	Discordance in <scp>HER2</scp> gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Medicine, 2013, 2, 226-233.	2.8	44
86	Cyclooxygenase-2 Induces Genomic Instability, BCL2 Expression, Doxorubicin Resistance, and Altered Cancer-Initiating Cell Phenotype in MCF7 Breast Cancer Cells. Journal of Surgical Research, 2008, 147, 240-246.	1.6	43
87	Improved Postoperative Pain Control using Thoracic Paravertebral Block for Breast Operations. Breast Journal, 2009, 15, 483-488.	1.0	42
88	Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer, 2010, 116, 2806-2814.	4.1	42
89	Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients WithÂInflammatory Breast Cancer Influences RadiationÂTreatment Field Designs. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1381-1386.	0.8	42
90	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research, 2020, 26, 1886-1895.	7.0	42

#	Article	IF	Citations
91	Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions. International Journal of Radiation Oncology Biology Physics, 2010, 76, 889-895.	0.8	39
92	Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control, 2016, 27, 359-366.	1.8	38
93	Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Annals of Oncology, 2013, 24, 2515-2521.	1.2	36
94	Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients. Cancer, 2006, 106, 188-195.	4.1	35
95	Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. Journal of the American College of Surgeons, 2016, 223, 20-29.	0.5	35
96	A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the american college of surgeons oncology group. Journal of the American College of Surgeons, 2004, 199, 644-651.	0.5	34
97	Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Research and Treatment, 2009, 117, 61-68.	2.5	34
98	Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2014, 147, 325-333.	2.5	32
99	Assessment of Knowledge of Melanoma Risk Factors, Prevention, and Detection Principles in Texas Teenagers. Journal of Surgical Research, 2001, 97, 179-183.	1.6	31
100	Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. European Journal of Cancer Care, 2015, 24, 724-733.	1.5	31
101	Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. Cancers, 2019, 11, 856.	3.7	31
102	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Annals of Surgical Oncology, 2017, 24, 2981-2988.	1.5	30
103	Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer?. Annals of Surgical Oncology, 2010, 17, 280-285.	1.5	29
104	Assessment of Practice Patterns Following Publication of the SSOâ€“ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer. Annals of Surgical Oncology, 2015, 22, 3250-3256.	1.5	29
105	Ductal Carcinoma In Situ and Margins <2â€Šmm. Annals of Surgery, 2019, 269, 150-157.	4.2	29
106	Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory BreastÂCancer. Clinical Breast Cancer, 2018, 18, e73-e77.	2.4	28
107	Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. Molecular and Clinical Oncology, 2014, 2, 845-850.	1.0	27
108	Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272.	2.5	27

#	Article	IF	Citations
109	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 242-247.	1.3	26
110	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv250.	6.3	25
111	Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast Journal, 2010, 16, 529-532.	1.0	24
112	Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer. Cancer, 2012, 118, 342-348.	4.1	24
113	Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Surgery, 2005, 138, 422-430.	1.9	23
114	Oncoplastics: Techniques for reconstruction of partial breast defects based on tumor location. Journal of Surgical Oncology, 2011, 103, 341-347.	1.7	23
115	Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Annals of Surgical Oncology, 2018, 25, 512-519.	1.5	23
116	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
117	Circulating Tumor Cells in Breast Cancer Patients. Critical Reviews in Oncogenesis, 2016, 21, 125-139.	0.4	22
118	Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin). Breast Journal, 2007, 13, 72-75.	1.0	21
119	Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. SpringerPlus, 2013, 2, 409.	1.2	21
120	Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?. Expert Review of Anticancer Therapy, 2007, 7, 1463-1472.	2.4	20
121	Cyclooxygenase-2 Expression Induces Genomic Instability in MCF10A Breast Epithelial Cells. Journal of Surgical Research, 2007, 140, 220-226.	1.6	20
122	Selection of Metastatic Breast Cancer Cells Based on Adaptability of Their Metabolic State. PLoS ONE, 2012, 7, e36510.	2.5	20
123	Mastectomy performed with scissors following tumescent solution injection. Journal of Surgical Oncology, 2003, 83, 191-193.	1.7	19
124	Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. Cancer Biology and Therapy, 2011, 11, 812-815.	3.4	19
125	Detection of circulating melanoma cells in the blood of melanoma patients. Melanoma Research, 2015, 25, 335-341.	1.2	19
126	Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2019, 26, 3071-3079.	1.5	19

#	Article	IF	Citations
127	The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database. Journal of Translational Medicine, 2019, 17, 318.	4.4	19
128	Phase II study of Radiumâ€223 dichloride combined with hormonal therapy for hormone receptorâ€positive, boneâ€dominant metastatic breast cancer. Cancer Medicine, 2020, 9, 1025-1032.	2.8	19
129	Circulating Tumor Cells in Breast Cancer. Recent Results in Cancer Research, 2020, 215, 127-145.	1.8	18
130	Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. American Journal of Surgery, 2006, 192, 541-544.	1.8	17
131	Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents. PLoS ONE, 2014, 9, e109487.	2.5	17
132	Circulating Tumor Cells in Stage IV Melanoma Patients. Journal of the American College of Surgeons, 2018, 227, 116-124.	0.5	17
133	Current Surgical Management of Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 5461-5467.	1.5	17
134	Cell-free circulating tumor DNA profiling in cancer management. Trends in Molecular Medicine, 2021, 27, 1014-1015.	6.7	17
135	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE, 2018, 13, e0204372.	2.5	16
136	American Society of Breast Surgeonsâ€™ Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Annals of Surgical Oncology, 2018, 25, 2965-2974.	1.5	16
137	Atypical Dermatofibrosarcoma Protuberans in the Breast. Breast Journal, 2005, 11, 217-218.	1.0	15
138	Overexpression of COX-2 in Celecoxib-Resistant Breast Cancer Cell Lines. Journal of Surgical Research, 2010, 163, 235-243.	1.6	15
139	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614.	2.5	15
140	Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. International Journal of Molecular Sciences, 2022, 23, 7843.	4.1	15
141	Disseminated Tumor Cells in Biologic Subtypes of Stage Iâ€“III Breast Cancer Patients. Annals of Surgical Oncology, 2010, 17, 3252-3258.	1.5	14
142	Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching â€˜liquid biopsyâ€™ and quantitative tumor modeling. BMC Cancer, 2018, 18, 903.	2.6	14
143	Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 4615-4622.	1.5	14
144	Lymphoscintigraphy Does Not Enhance Sentinel Node Identification or Alter Management of Patients With Early Breast Cancer. Journal of Surgical Education, 2006, 63, 207-212.	0.7	13

#	Article	IF	Citations
145	Assessment of the Current Medicare Reimbursement System for Breast Cancer Operations. Annals of Surgical Oncology, 2004, 11, 1037-1044.	1.5	12
146	Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. American Journal of Surgery, 2005, 190, 598-601.	1.8	12
147	Surgical Treatment of Pregnancy Associated Breast Cancer. Breast Disease, 2006, 23, 87-93.	0.8	12
148	Management of Local-Regional Recurrence following Immediate Breast Reconstruction in Patients with Early Breast Cancer Treated without Postmastectomy Radiotherapy. Plastic and Reconstructive Surgery, 2011, 127, 1763-1772.	1.4	12
149	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology, 2020, 27, 4603-4612.	1.5	12
150	Invasive lobular carcinoma predicts micrometastasis in breast cancer. Journal of Surgical Research, 2012, 177, 93-96.	1.6	11
151	Aldehyde Dehydrogenase1 Immunohistochemical Staining in Primary Breast Cancer Cells Independently Predicted Overall Survival But Did Not Correlate with the Presence of Circulating or Disseminated Tumors Cells. Journal of Cancer, 2014, 5, 360-367.	2.5	11
152	The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 4265-4274.	1.5	11
153	OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Annals of Surgical Oncology, 2019, 26, 815-820.	1.5	10
154	A usable model of â€œdecathlon winnerâ€•cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence. Oncotarget, 2018, 9, 11071-11082.	1.8	10
155	Relapse of Thrombotic Thrombocytopenic Purpura Associated with Decreased VWF Cleaving Activity. American Journal of the Medical Sciences, 2002, 323, 281-284.	1.1	9
156	Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. Journal of Surgical Research, 2019, 243, 90-99.	1.6	9
157	Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. Oncotarget, 2021, 12, 626-637.	1.8	9
158	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022, 6, e2000368.	3.0	9
159	Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. American Journal of Surgery, 2017, 214, 666-671.	1.8	8
160	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Practical Radiation Oncology, 2019, 9, 402-409.	2.1	8
161	Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Oncotarget, 2019, 10, 3681-3693.	1.8	8
162	Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. Journal of Investigative Dermatology, 2022, 142, 2046-2049.e3.	0.7	8

#	Article	IF	Citations
163	Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Research and Treatment, 2012, 133, 1131-1141.	2.5	7
164	Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. Journal of Investigative Dermatology, 2015, 135, 2266-2272.	0.7	7
165	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489.	1.5	7
166	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 8610-8621.	1.5	7
167	Impact of the early COVIDâ€19 pandemic on Breast Surgical Oncology fellow education. Journal of Surgical Oncology, 2021, 124, 989-994.	1.7	7
168	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 1888-1889.	27.0	6
169	Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis.. Journal of Clinical Oncology, 2018, 36, 1065-1065.	1.6	6
170	Contemporary surgical management of inflammatory breast cancer: a narrative review. Chinese Clinical Oncology, 2021, 10, 57-57.	1.2	6
171	Giant pelvic schwannoma with ancient change. Journal of the American College of Surgeons, 2003, 197, 163.	0.5	5
172	The relationship between blood <scp>IL</scp>â€12p40 level and melanoma progression. International Journal of Cancer, 2015, 136, 1874-1880.	5.1	5
173	Inflammatory Breast Cancer at the Extremes of Age. Annals of Surgical Oncology, 2021, 28, 5626-5634.	1.5	5
174	Orthopedic surgery implications of breast cancer. Expert Review of Anticancer Therapy, 2008, 8, 949-956.	2.4	4
175	Reply to K.J. Van Zee et al. Journal of Clinical Oncology, 2012, 30, 3144-3145.	1.6	4
176	In response to â€œoutcomes of patients with inflammatory breast cancer treated by breast conserving surgeryâ€: the argument against breast conservation and sentinel lymph node biopsy in IBC. Breast Cancer Research and Treatment, 2017, 165, 779-781.	2.5	4
177	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer, 2020, 20, 430.	2.6	4
178	Intramammary Lymph Node Presenting as the Primary Breast Mass in Infiltrating Lobular Carcinoma. Journal of Surgical Education, 2006, 63, 107-109.	0.7	3
179	The suture scaffold technique for improved cosmesis in partial mastectomy defects. Journal of Surgical Oncology, 2010, 102, 184-186.	1.7	3
180	Best practices for multidisciplinary integration of a DCIS genomic assay into clinical practice. Journal of Surgical Oncology, 2017, 116, 1016-1020.	1.7	3

#	Article	IF	Citations
181	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. Journal of Cancer, 2019, 10, 2635-2642.	2.5	3
182	Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, 28, 5477-5485.	1.5	3
183	Immediate Breast Reconstruction in Inflammatory Breast Cancer: Are We There Yet?. Annals of Surgical Oncology, 2022, , .	1.5	3
184	RE: Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer, by van Rijk MC, Tanis PJ, Nieweg OE, et al.. Journal of Surgical Oncology, 2006, 94, 266-268.	1.7	2
185	Is axillary dissection needed when the sentinel node is positive? No: It is time to rethink axillary lymph node dissection when the sentinel node is positive. Journal of Surgical Oncology, 2008, 97, 201-202.	1.7	2
186	Reply to â€˜A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18â€™. Breast, 2018, 39, 148-149.	2.2	2
187	Mammalian Expression and In Situ Biotinylation of Extracellular Protein Targets for Directed Evolution. ACS Omega, 2020, 5, 25440-25455.	3.5	2
188	Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. Breast Cancer Research and Treatment, 2020, 184, 683-687.	2.5	2
189	ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 458-459.	1.5	2
190	ASO Visual Abstract: Inflammatory Breast Cancer at the Extremes of Age. Annals of Surgical Oncology, 2021, 29, 389.	1.5	2
191	Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Annals of Surgical Oncology, 0, , .	1.5	2
192	Assessment of the Current Medicare Reimbursement System for Breast Cancer Operations. Breast Diseases, 2005, 16, 111-114.	0.0	1
193	Prospective Studies Confirm What We Have Thought All Alongâ€”Sentinel Lymph Node Dissection Really Is a Less Morbid Means of Axillary Staging. Breast Diseases, 2007, 18, 18.	0.0	1
194	Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer. Current Breast Cancer Reports, 2019, 11, 52-66.	1.0	1
195	ASO Author Reflection: Axillary Dissection for Negative Lymph Nodes in Inflammatory Breast Cancerâ€”Need for Clinical Trials to Reassess Standard of Care. Annals of Surgical Oncology, 2020, 27, 676-677.	1.5	1
196	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers, 2020, 12, 3105.	3.7	1
197	Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: The potential role of partial breast irradiation. Women's Oncology Review, 2005, 5, 75-76.	0.0	1
198	Trends in Sentinel Lymph Node Biopsies in Patients With Inflammatory Breast Cancer in the US. JAMA Network Open, 2022, 5, e2148021.	5.9	1

#	Article	IF	Citations
199	Utilization and evolving prescribing practice of opioid and nonâ€opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. Journal of Surgical Oncology, 2022, 125, 719-729.	1.7	1
200	Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers, 2022, 14, 2631.	3.7	1
201	Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: The potential role of partial breast irradiation. Women's Oncology Review, 2005, 5, 75-76.	0.0	0
202	4â€“24 Nipple-Sparing Mastectomy for Breast Cancer and Risk Reduction: Oncologic or Technical Problem?. Breast Diseases, 2008, 18, 370-371.	0.0	0
203	Micrometastatic Node-Positive Breast Cancer: Long-Term Outcomes and Identification of High-Risk Subsets in a Large Population-Based Series. Breast Diseases, 2011, 22, 51-53.	0.0	0
204	Anti-cytokeratin CAM5.2 (BD Sciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage Iâ€“III Breast Cancer Patients. Annals of Surgical Oncology, 2011, 18, 263-264.	1.5	0
205	Reply to detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer, 2011, 117, 2579-2579.	4.1	0
206	Circulating and Disseminated Tumor Cells in Breast Cancer. Breast Diseases, 2012, 23, 314-317.	0.0	0
207	Circulating tumour cells in early breast cancer â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e371.	10.7	0
208	Detection and prognostic significance of circulating tumor cells in nonmetastatic breast cancer patients. Breast Cancer Management, 2013, 2, 295-309.	0.2	0
209	Molecular Prognostic Factors for Breast Carcinoma. , 2018, , 258-263.e2.		0
210	Can Circulating Tumor Cell Monitoring Identify Optimal Candidates for Watch and Wait after Neoadjuvant Therapy for Rectal Cancer?. Journal of the American College of Surgeons, 2018, 227, S61.	0.5	0
211	Nipple sparing mastectomy for melanoma metastatic to the breast. Breast Journal, 2019, 25, 741-741.	1.0	0
212	ASO Author Reflections: The Multidisciplinary Approach to de Novo Metastatic Inflammatory Breast Cancer: A Combined Systemic and Locoregional Strategy. Annals of Surgical Oncology, 2021, 28, 4275-4276.	1.5	0
213	ASO Author Reflections: Metastasis of Inflammatory Breast Cancer to the Contralateral Axilla: A Finding Meriting Further Study. Annals of Surgical Oncology, 2021, 28, 8622-8623.	1.5	0
214	Site of primary tumor has a prognostic role in operable breast cancer: The International Breast Cancer Group experienceM. Colleoni, D. Zahrieh, R.D. Gelber, S.B. Holmberg, J.E. Mattsson, C.-M. Rudenstam, J. Lindtner, D. Erzen, R. Snyder, J. Collins, et al. JCO 2005;23(7):1390â€“1400. Women's Oncology Review, 2005, 5, 173-174.	0.0	0
215	Surgical Therapy for Inflammatory Breast Cancer. , 2012, , 67-73.		0
216	Opioid prescriptions after breast cancer surgery: Perception and reality.. Journal of Clinical Oncology, 2018, 36, e18799-e18799.	1.6	0

#	Article	IF	Citations
217	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	0
218	ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Annals of Surgical Oncology, 2021, , 1.	1.5	0
219	Therapeutics of Oxidative Stress and Stemness in Breast Cancer. , 2022, , 1765-1776.		0